サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1413660

膣炎治療薬市場：薬剤タイプ、提供、投与経路、流通チャネル別 - 世界予測、2024年～2030年

Vaginitis Therapeutics Market by Drug Type (Anti-bacterial, Anti-fungal, Hormone), Offering (Over-The-Counter (OTC), Prescription), Route of Administration, Distribution Channel - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 196 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.97円
膣炎治療薬市場：薬剤タイプ、提供、投与経路、流通チャネル別 - 世界予測、2024年～2030年
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 196 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

膣炎治療薬市場規模は2023年に26億米ドルと推計され、2024年には27億6,000万米ドルに達し、CAGR 8.75%で2030年には46億8,000万米ドルに達すると予測されます。

膣炎治療薬の世界市場

主な市場の統計
基準年[2023年］ 26億米ドル
予測年[2024年］ 27億6,000万米ドル
予測年 [2030年] 46億8,000万米ドル
CAGR（%） 8.75%
膣炎治療薬 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは膣炎治療薬市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、膣炎治療薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-膣炎治療薬市場の市場規模および予測は？

2-膣炎治療薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-膣炎治療薬市場における技術動向と規制の枠組みは？

4-膣炎治療薬市場における主要ベンダーの市場シェアは？

5-膣炎治療薬市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 感染症による膣炎の有病率の上昇
      • 性的健康が女性に与える影響についての意識の高まり
      • 低侵襲医療処置と先進的な膣製品に対する嗜好の高まり
    • 抑制要因
      • 膣炎の治療には高額な費用がかかる
    • 機会
      • 膣感染症を治療するための診断と治療における技術の進歩
      • 膣炎治療用のジェルやクリームなどの標的送達システムの需要
    • 課題
      • 膣炎薬の使用に伴う副作用
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 膣炎治療薬市場薬剤の種類別

  • 抗菌
  • 抗真菌
  • ホルモン

第7章 膣炎治療薬市場：提供別

  • 店頭販売（OTC）
  • 処方箋

第8章 膣炎治療薬市場：投与経路別

  • 経口
  • 局所

第9章 膣炎治療薬市場：流通チャネル別

  • 病院
  • 薬局
    • オフライン
    • オンライン

第10章 南北アメリカの膣炎治療薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第11章 アジア太平洋の膣炎治療薬市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第12章 欧州・中東・アフリカの膣炎治療薬市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第13章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第14章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • AbbVie Inc.
    • Bausch Health Companies Inc.
    • Bayer AG
    • Cipla Ltd.
    • Dare Bioscience, Inc.
    • Dr Reddy's Laboratories Ltd
    • Eli Lilly and Company
    • Enzo Biochem Inc.
    • Janssen Pharmaceuticals Inc.
    • Lumavita AG
    • Lupin Pharmaceuticals Inc.
    • Merck & Co., Inc.
    • Mission Pharmacal Company
    • Mylan NV
    • Novartis AG
    • Novo Nordisk A/S
    • Perrigo Company plc
    • Pfizer Inc.
    • PhagoMed Biopharma GmbH
    • Sanofi S.A.
    • Starpharma Holdings Limited
    • Sun Pharmaceutical Industries Limited
    • TenNor Therapeutics Ltd
    • Teva Pharmaceutical Industries Ltd.
    • Tolmar Pharmaceuticals, Inc.
  • 主要な製品ポートフォリオ

第15章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. VAGINITIS THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. VAGINITIS THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. VAGINITIS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. VAGINITIS THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. VAGINITIS THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. VAGINITIS THERAPEUTICS MARKET DYNAMICS
  • FIGURE 7. VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 8. VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
  • FIGURE 10. VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 12. VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 14. VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. VAGINITIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 24. VAGINITIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. VAGINITIS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. VAGINITIS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 6. VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTI-BACTERIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTI-FUNGAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. VAGINITIS THERAPEUTICS MARKET SIZE, BY HORMONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 10. VAGINITIS THERAPEUTICS MARKET SIZE, BY OVER-THE-COUNTER (OTC), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. VAGINITIS THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 13. VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 16. VAGINITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 19. VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. VAGINITIS THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. INDIA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 71. INDIA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. INDIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 74. INDONESIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. INDONESIA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 76. INDONESIA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. INDONESIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 79. JAPAN VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. JAPAN VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 81. JAPAN VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. JAPAN VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 84. MALAYSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. MALAYSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 86. MALAYSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. MALAYSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 89. PHILIPPINES VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. PHILIPPINES VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 91. PHILIPPINES VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. PHILIPPINES VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. PHILIPPINES VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 94. SINGAPORE VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. SINGAPORE VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 96. SINGAPORE VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. SINGAPORE VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. SINGAPORE VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 99. SOUTH KOREA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. SOUTH KOREA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 101. SOUTH KOREA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. SOUTH KOREA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. SOUTH KOREA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 104. TAIWAN VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. TAIWAN VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 106. TAIWAN VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. TAIWAN VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. TAIWAN VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 109. THAILAND VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. THAILAND VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 111. THAILAND VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. THAILAND VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. THAILAND VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 114. VIETNAM VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. VIETNAM VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 116. VIETNAM VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. VIETNAM VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. VIETNAM VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 125. DENMARK VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. DENMARK VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 127. DENMARK VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. DENMARK VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. DENMARK VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 130. EGYPT VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. EGYPT VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 132. EGYPT VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. EGYPT VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. EGYPT VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 135. FINLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. FINLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 137. FINLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. FINLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. FINLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 140. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 142. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. FRANCE VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 145. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 147. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 149. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 150. ISRAEL VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. ISRAEL VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 152. ISRAEL VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. ISRAEL VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. ISRAEL VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 155. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 157. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 158. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 159. ITALY VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 160. NETHERLANDS VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. NETHERLANDS VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 162. NETHERLANDS VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. NETHERLANDS VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. NETHERLANDS VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 165. NIGERIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. NIGERIA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 167. NIGERIA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. NIGERIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 169. NIGERIA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 170. NORWAY VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. NORWAY VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 172. NORWAY VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. NORWAY VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. NORWAY VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 175. POLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. POLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 177. POLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. POLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. POLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 180. QATAR VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. QATAR VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 182. QATAR VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. QATAR VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. QATAR VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 185. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 187. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. RUSSIA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 190. SAUDI ARABIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. SAUDI ARABIA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 192. SAUDI ARABIA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 193. SAUDI ARABIA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. SAUDI ARABIA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 195. SOUTH AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. SOUTH AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 197. SOUTH AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 198. SOUTH AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 200. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 202. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 203. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 204. SPAIN VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 205. SWEDEN VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SWEDEN VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 207. SWEDEN VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. SWEDEN VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 209. SWEDEN VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 210. SWITZERLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. SWITZERLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 212. SWITZERLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 213. SWITZERLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 214. SWITZERLAND VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 215. TURKEY VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. TURKEY VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 217. TURKEY VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 218. TURKEY VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 219. TURKEY VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 220. UNITED ARAB EMIRATES VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. UNITED ARAB EMIRATES VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 222. UNITED ARAB EMIRATES VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 223. UNITED ARAB EMIRATES VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 230. VAGINITIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 231. VAGINITIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 232. VAGINITIS THERAPEUTICS MARKET LICENSE & PRICING
目次
Product Code: MRR-8E22B61932E8

[196 Pages Report] The Vaginitis Therapeutics Market size was estimated at USD 2.60 billion in 2023 and expected to reach USD 2.76 billion in 2024, at a CAGR 8.75% to reach USD 4.68 billion by 2030.

Global Vaginitis Therapeutics Market

KEY MARKET STATISTICS
Base Year [2023] USD 2.60 billion
Estimated Year [2024] USD 2.76 billion
Forecast Year [2030] USD 4.68 billion
CAGR (%) 8.75%
Vaginitis Therapeutics Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Vaginitis Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Vaginitis Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Vaginitis Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Bausch Health Companies Inc., Bayer AG, Cipla Ltd., Dare Bioscience, Inc., Dr Reddy's Laboratories Ltd, Eli Lilly and Company, Enzo Biochem Inc., Janssen Pharmaceuticals Inc., Lumavita AG, Lupin Pharmaceuticals Inc., Merck & Co., Inc., Mission Pharmacal Company, Mylan NV, Novartis AG, Novo Nordisk A/S, Perrigo Company plc, Pfizer Inc., PhagoMed Biopharma GmbH, Sanofi S.A., Starpharma Holdings Limited, Sun Pharmaceutical Industries Limited, TenNor Therapeutics Ltd, Teva Pharmaceutical Industries Ltd., and Tolmar Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Vaginitis Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Type
    • Anti-bacterial
    • Anti-fungal
    • Hormone
  • Offering
    • Over-The-Counter (OTC)
    • Prescription
  • Route of Administration
    • Oral
    • Topical
  • Distribution Channel
    • Hospital
    • Pharmacies
      • Offline
      • Online
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Vaginitis Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Vaginitis Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Vaginitis Therapeutics Market?

4. What is the market share of the leading vendors in the Vaginitis Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Vaginitis Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Vaginitis Therapeutics Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of vaginitis caused by infections
      • 5.1.1.2. Increasing awareness about the impacts of sexual health on women
      • 5.1.1.3. Growing preference for minimally invasive medical procedures and advanced vaginal products
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with the treatment of vaginitis
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancement in diagnostics and therapeutics for treating vaginal infections
      • 5.1.3.2. Demand for targeted delivery systems such as gels and creams for treating vaginitis
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with the use of vaginitis medications
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Vaginitis Therapeutics Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Anti-bacterial
  • 6.3. Anti-fungal
  • 6.4. Hormone

7. Vaginitis Therapeutics Market, by Offering

  • 7.1. Introduction
  • 7.2. Over-The-Counter (OTC)
  • 7.3. Prescription

8. Vaginitis Therapeutics Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Oral
  • 8.3. Topical

9. Vaginitis Therapeutics Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital
  • 9.3. Pharmacies
    • 9.4.1. Offline
    • 9.4.2. Online

10. Americas Vaginitis Therapeutics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Vaginitis Therapeutics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Vaginitis Therapeutics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. FPNV Positioning Matrix
  • 13.2. Market Share Analysis, By Key Player
  • 13.3. Competitive Scenario Analysis, By Key Player

14. Competitive Portfolio

  • 14.1. Key Company Profiles
    • 14.1.1. AbbVie Inc.
    • 14.1.2. Bausch Health Companies Inc.
    • 14.1.3. Bayer AG
    • 14.1.4. Cipla Ltd.
    • 14.1.5. Dare Bioscience, Inc.
    • 14.1.6. Dr Reddy's Laboratories Ltd
    • 14.1.7. Eli Lilly and Company
    • 14.1.8. Enzo Biochem Inc.
    • 14.1.9. Janssen Pharmaceuticals Inc.
    • 14.1.10. Lumavita AG
    • 14.1.11. Lupin Pharmaceuticals Inc.
    • 14.1.12. Merck & Co., Inc.
    • 14.1.13. Mission Pharmacal Company
    • 14.1.14. Mylan NV
    • 14.1.15. Novartis AG
    • 14.1.16. Novo Nordisk A/S
    • 14.1.17. Perrigo Company plc
    • 14.1.18. Pfizer Inc.
    • 14.1.19. PhagoMed Biopharma GmbH
    • 14.1.20. Sanofi S.A.
    • 14.1.21. Starpharma Holdings Limited
    • 14.1.22. Sun Pharmaceutical Industries Limited
    • 14.1.23. TenNor Therapeutics Ltd
    • 14.1.24. Teva Pharmaceutical Industries Ltd.
    • 14.1.25. Tolmar Pharmaceuticals, Inc.
  • 14.2. Key Product Portfolio

15. Appendix

  • 15.1. Discussion Guide
  • 15.2. License & Pricing